Five Oaks Investment Corp. OAKS 深 滬
等待開盤 10-28 09:30:00 美东时间
3.43
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.43
- 總市值 7593.28万
- 52周最高 5.60
- 市盈率 靜 403.53
- 換手率 0.00%
- 52周最低 2.55
- 委 比 0.00%
- 總股本 2213.78万
- 歷史最高 15.71
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2.55
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SEI Increases Stock Share Repurchase Program by $650 Million
OAKS, Pa., Oct. 24, 2025 /PRNewswire/ -- The Board of Directors of SEI Investments Company approved an increase in its stock repurchase program by an additional $650 million, increasing the ...
10-25 04:25
Amgen Announces FDA Approval Of TEZSPIRE For Chronic Rhinosinusitis With Nasal Polyps In Patients Aged 12 And Older, Expands Use To Second Epithelial-Driven Disease
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation
10-18 04:02
SEI to Announce Third-Quarter 2025 Earnings on Wednesday, October 22, 2025
Public Invited to Monitor Conference Call at 5 p.m. Eastern Time OAKS, Pa., Oct. 9, 2025 /PRNewswire/ -- SEI® (NASDAQ: SEIC) intends to release earnings for the third quarter 2025 on Wednesd...
10-09 21:00
Amgen Announces The Phase 3 VESALIUS-CV Clinical Trial Met Its Dual Primary Endpoints Demonstrating That Repatha Significantly Reduced The Risk Of Major Adverse Cardiovascular Events In Individuals Without A Prior History Of Heart Attack Or Stroke
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy AloneRepatha is Now the First and Only PCSK9 Inhibitor to
10-02 21:18
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The plan...
09-26 21:00
Amgen To Invest Over $600M In New U.S. Science And Innovation Center, Creating Hundreds Of Jobs
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to invest more than $600
09-02 21:04
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m. ET on Wednesday, Sept. 3, 2025. Paul Burton,...
08-30 04:01
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The div...
08-02 04:01
SEI And Stratos Wealth Holdings Enter Into Business Partnership, Underscored By Shared Commitment To Helping Advisors Scale And Grow Businesses
Partnership Reinforces Value of Advice, Delivering Wealth Management and Services at ScaleOAKS, Pa., July 18, 2025 /PRNewswire/ -- SEI® (NASDAQ:SEIC) and Stratos Wealth Holdings today announced that they have
07-18 20:02
Amgen Announces Full Results From Part 1 Of Phase 2 Study Of MariTide; Presents Complete Results From Primary Analysis Of Phase 1 PK-LDI Study Evaluating Lower Starting Doses Of MariTide At ADA 85th Scientific Sessions
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 WeeksIn
06-24 02:33
